arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

AN2 Therapeutics, Inc.

ANTX

$5.92 ▼ -0.17 (-2.79%) at close

22 Visible periods

17 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

AN2 Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $201.6M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -10.2% ↗

FCF / Share $-0.35

Trailing P/E —

Price / Book 2.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

22-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-10.03M

↑ +5.8% —

FCF / Share Free cash flow per share

$-0.35

— -0.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
EPS Growth YoY (%)	17.1% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	-12.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	27.9% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	56.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	37.5% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	51.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	33.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	40.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	29.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	10.3% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-10.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-52.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	—	83.8% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	82.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	79.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	5.8% Fair ↓ Fair Declining Year-over-year change in net income	-15.3% Weak ↓ Weak Declining Year-over-year change in net income	35.9% Excellent ↓ Excellent Declining Year-over-year change in net income	35.9% Excellent ↑ Excellent Improving Year-over-year change in net income	35.9% Excellent ↑ Excellent Improving Year-over-year change in net income	55.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-8.4% Weak ↑ Weak Improving Year-over-year change in net income	-8.4% Weak ↑ Weak Improving Year-over-year change in net income	-8.4% Weak ↑ Weak Improving Year-over-year change in net income	-43.0% Weak ↑ Weak Improving Year-over-year change in net income	-100.2% Weak ↓ Weak Declining Year-over-year change in net income	-100.2% Weak ↑ Weak Improving Year-over-year change in net income	-100.2% Weak ↑ Weak Improving Year-over-year change in net income	-57.0% Weak ↑ Weak Improving Year-over-year change in net income	-273.8% Weak → Weak Stable Year-over-year change in net income	-273.8% Weak Weak Year-over-year change in net income	-273.8% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	-0.3% Weak Weak Year-over-year change in free cash flow	—	—	—	40.2% Excellent Excellent Year-over-year change in free cash flow	—	—	—	1.2% Caution Caution Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
FCF / Net Income (x)	1.20x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.00x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	1.06x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	0.76x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	0.88x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.19x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	2.29x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	2.57x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-10.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-13.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-12.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-12.6% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-12.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-10.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-14.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-15.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	12.7% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	14.3% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	13.2% Good Good Return earned on debt + equity capital invested Optimal: > 10%	8.0% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-12.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-15.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-14.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-14.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-14.3% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-14.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-13.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-11.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-16.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-17.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.6% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-6.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-11.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-12.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-182%)	-16.3% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-209%)	-17.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-218%)	-15.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-203%)	-14.5% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-197%)	-9.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-161%)	-19.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-226%)	-16.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-213%)	-15.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-200%)	-13.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-191%)	-11.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-174%)	-17.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-216%)	-18.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-224%)	-12.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-183%)	-7.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-148%)	-6.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-144%)	-6.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-144%)	15.9% Good ↑ Good Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+6%)	5.3% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-64%)	6.9% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-54%)	10.1% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-33%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Net Debt (USD)	$-53.49M	$-19.94M	$-18.00M	$-18.22M	$-19.98M	$-21.35M	$-33.50M	$-26.77M	$-24.69M	$-15.65M	$-32.62M	$-40.81M	$-26.71M	$-27.22M	$-28.80M	$-40.62M	$-82.52M	$-12.10M	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-0.29	$-0.28	$-0.31	$-0.21	$-0.35	$-0.25	$-0.43	$-0.48	$-0.56	$-0.52	$-0.65	$-0.81	$-0.79	$-0.58	$-0.59	$-0.53	—	$-3.58	$-3.35	$-2.62	—	—
Free Cash Flow per Share (USD)	$-0.35	—	$-0.21	$-0.25	$-0.35	—	—	—	$-0.59	—	—	—	$-0.60	—	—	—	—	—	$-1.77	$-2.00	—	—
Book Value per Share (USD)	$2.27	$1.94	$2.21	$2.51	$2.43	$2.74	$2.94	$3.30	$3.71	$4.19	$4.67	$4.00	$4.25	$4.92	$5.44	$5.97	$6.17	$-17.36	$-14.50	$-11.33	—	—
Tangible Book Value per Share (USD)	$2.27	$1.94	$2.21	$2.51	$2.43	$2.74	$2.94	$3.30	$3.71	$4.19	$4.67	$4.00	$4.25	$4.92	$5.44	$5.97	$6.17	$-17.36	$-14.50	$-11.33	—	—
Basic Weighted Avg Shares (shares)	34.06M	—	30.28M	30.17M	30.05M	—	29.84M	29.82M	29.76M	—	25.65M	19.50M	19.39M	—	19.35M	19.26M	—	—	2.64M	2.63M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$81.93M	$51.22M	—	—	—	$76.02M	$87.67M	—	—	—	$111.57M	$87.05M	$81.75M	$91.44M	$102.86M	$112.73M	$114.70M	$56.71M	—	—	—	—
Total Equity (USD)	$81.76M	$53.06M	$60.38M	$68.84M	$73.33M	$81.85M	$87.67M	$98.35M	$110.60M	$124.70M	$138.97M	$87.76M	$82.52M	$95.37M	$105.57M	$115.86M	$115.41M	$-47.41M	$-38.35M	$-29.84M	$-20.32M	$-20.32M

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Net Income, GAAP (USD)	$-10.03M	$-8.67M	$-10.65M	$-10.65M	$-10.65M	$-7.52M	$-16.62M	$-16.62M	$-16.62M	$-16.93M	$-15.32M	$-15.32M	$-15.32M	$-11.84M	$-7.66M	$-7.66M	$-7.66M	$-7.54M	$-2.05M	$-2.05M	$-2.05M	—
Operating Cash Flow (USD)	$-12.07M	$-5.24M	$-6.38M	$-7.60M	$-10.62M	$-5.27M	—	—	$-17.59M	$-17.07M	—	—	$-11.60M	$-7.64M	—	—	$-6.74M	$-8.99M	$-4.69M	$-5.26M	$-1.54M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters

AN2 Therapeutics, Inc.

Analytical Summary

22-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ANTX with peers